Division of Immunology, Paul-Ehrlich-Institut, Langen, Germany.
Eur J Immunol. 2010 Oct;40(10):2769-77. doi: 10.1002/eji.201040453.
Virus-induced expansion of CD8(+) T cells may be promoted by type I IFN receptor (IFNAR)-triggering of T cells, depending on the pathogen tested. We studied modified vaccinia virus Ankara (MVA), a promising vaccine vector candidate, which was derived from conventional vaccinia virus (VACV) by more than 570 consecutive in vitro passages. In adoptive transfer experiments, we verified that VACV expressing the gp33 epitope of lymphocytic choriomeningitis virus (VACV(gp33)) induced largely IFNAR-independent expansion of gp33-specific T cells. On the contrary, MVA(gp33)-induced T-cell expansion was IFNAR dependent. Interestingly, under the latter conditions, T-cell activation was IFNAR independent, whereas T-cell apoptosis was enhanced in the absence of IFNAR. To address whether MVA-induced T-cell expansion was solely affected by IFNAR-triggering of T cells, expansion of endogenous T cells was studied in conditional mice with a T-cell- or DC-specific IFNAR deletion. Interestingly, both mouse strains showed moderately reduced T-cell expansion, whereas mice with a combined T-cell- and DC-specific IFNAR ablation showed massively reduced T-cell expansion similar to that of IFNAR(-/-) mice. These results are compatible with the model that IFN-inducing viruses such as MVA confer virus-specific CD8(+) T-cell expansion by concomitant IFNAR-triggering of DC and of T cells.
病毒诱导的 CD8(+)T 细胞扩增可能取决于所检测的病原体,通过 I 型干扰素受体(IFNAR)触发 T 细胞来促进。我们研究了改良安卡拉牛痘病毒(MVA),它是一种很有前途的候选疫苗载体,是通过超过 570 次连续的体外传代从常规牛痘病毒(VACV)衍生而来的。在过继转移实验中,我们验证了表达淋巴细胞性脉络丛脑膜炎病毒 gp33 表位的 VACV(VACV(gp33))诱导的 gp33 特异性 T 细胞扩增在很大程度上不依赖于 IFNAR。相反,MVA(gp33)诱导的 T 细胞扩增依赖于 IFNAR。有趣的是,在后一种情况下,T 细胞的激活不依赖于 IFNAR,但在没有 IFNAR 的情况下,T 细胞凋亡增强。为了解决 MVA 诱导的 T 细胞扩增是否仅受 T 细胞 IFNAR 触发的影响,我们在条件性敲除 T 细胞或 DC 特异性 IFNAR 的小鼠中研究了内源性 T 细胞的扩增。有趣的是,两种小鼠品系的 T 细胞扩增均适度减少,而 T 细胞和 DC 特异性 IFNAR 双敲除的小鼠的 T 细胞扩增则明显减少,类似于 IFNAR(-/-)小鼠的情况。这些结果与以下模型一致,即像 MVA 这样的诱导 IFN 的病毒通过同时触发 DC 和 T 细胞的 IFNAR 来赋予病毒特异性 CD8(+)T 细胞扩增。